Personalized tumor neoantigen vaccine approved for clinical use.

Lowering the risk of cancer recurrence after surgery, personalized tumor neoantigen vaccines bring new therapeutic options. Yesterday, reporters learned from Zhongguancun Life Science Park that the mRNA personalized tumor neoantigen vaccine XH001 developed independently by the park's enterprise, NewLinker Bio, has recently been approved by the National Medical Products Administration Drug Evaluation Center to start clinical trials. This means that in the future, personalized treatment based on the patient's tumor mutation spectrum can be tailored to achieve "one drug per person", bringing hope to solving the difficult problem of cancer recurrence after radical treatment.